Rossari Biotech Ltd (ROSSARI) AI Stock Analysis

• Market Cap: ₹31.54B
• Dividend Yield: 0.09%
• Average Volume (3M): 2.66K
• Price to Earnings (P/E): 23.1
• Beta (1Y): 0.91
• Revenue Growth: 15.47%
• EPS Growth: -1.72%
• Country: IN
• Employees: 450
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals - Specialty
• EPS (TTM): 6.70
• Shares Outstanding: 55,381,367
• 10 Day Avg. Volume: 1,386
• 30 Day Avg. Volume: 2,661
• PEG Ratio: 5.98
• Price to Book (P/B): 2.88
• Price to Sales (P/S): 1.64
• P/FCF Ratio: -161.88
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 2,467
• Revenue Forecast (FY): ₹2.11T

• Rating: 70 Outperform
• Price Target: ₹712.00 ▲(22.83% Upside)

Rossari Biotech Ltd shows strong financial performance with robust revenue growth and low leverage, but faces challenges with free cash flow. Technical indicators suggest mild bullish momentum, while valuation metrics indicate moderate pricing. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Revenue Growth

Consistent revenue growth indicates robust demand for Rossari's products, enhancing its market position and supporting long-term business expansion.

Low Leverage

Low leverage provides Rossari Biotech with financial flexibility, reducing risk and enabling strategic investments without significant debt burden.

Profitability

Strong profitability margins reflect effective cost management and operational efficiency, supporting sustainable earnings growth.

Negative Factors

Negative Free Cash Flow

Negative free cash flow can constrain Rossari's ability to fund growth initiatives and manage liquidity, posing long-term financial challenges.

EBITDA Margin Pressure

Decreasing EBITDA margin suggests potential challenges in maintaining operational efficiency, which could impact cash generation and profitability.

EPS Growth Decline

Declining EPS growth may signal challenges in profit expansion, potentially affecting investor confidence and long-term valuation.

Rossari Biotech Ltd Business Overview & Revenue Model

Company Description

Rossari Biotech Limited engages in manufacture and sale of specialty chemicals in India and internationally. It offers soap and detergents; inks, paints, and coatings; ceramics and tiles; pulp and papers; cement; and water treatment solutions. The company also provides textile specialty chemicals, such as cotton, polyester, acrylic, wool, silk, nylon, functional finishes, denim, and sustainable solutions; and pet grooming products, which include natural pet shampoos, powders, deodorants, sprays, creams, and floor washing liquids under the Lozalo, Hunger Fills, and Sniffy brand names. In addition, it provides poultry nutrition products comprising vitamin-mineral formulations, toxin binders, individual and cocktail enzymes, liquid nutraceuticals, and supplements or herbal preparations. The company was formerly known as Rossari Labtech and changed its name to Rossari Biotech Limited in December 2003. Rossari Biotech Limited was founded in 2003 and is based in Mumbai, India.

How the Company Makes Money

Rossari Biotech generates revenue through the sale of its specialized chemical products, which cater to multiple industries including textiles, apparel, and home care. The company’s primary revenue streams come from the direct sale of its products to manufacturers who use these chemicals in their production processes. Additionally, ROSSARI has established significant partnerships with various industries, enhancing its market presence and distribution capabilities. The company also invests in research and development to innovate new products, which can lead to increased sales and market penetration. Furthermore, the growing demand for sustainable and eco-friendly products contributes to its revenue growth, as consumers and businesses alike are increasingly seeking greener alternatives.

Rossari Biotech Ltd Financial Statement Overview

Summary

Rossari Biotech Ltd exhibits strong revenue growth and profitability, with efficient use of equity and low leverage. However, the company faces challenges in generating positive free cash flow due to high capital expenditures.

Income Statement

Rossari Biotech Ltd has demonstrated a strong revenue growth rate of 13.65% from 2024 to 2025, with a notable improvement in both gross profit margin (31.10%) and EBIT margin (24.74%) in 2025. Net profit margin increased slightly to 6.55%, reflecting efficient cost management and operational performance. However, EBITDA margin decreased slightly to 12.74%, indicating some pressure on operational cash generation.

Balance Sheet

The company's debt-to-equity ratio is relatively low at 0.18, indicating low leverage and a strong equity position. The return on equity improved to 11.51%, demonstrating effective use of equity to generate profits. The equity ratio stands at 62.51%, indicating a solid financial structure with a significant portion of assets funded by equity.

Cash Flow

Operating cash flow to net income ratio is 1.01, showing that operating cash flow adequately covers net income. However, free cash flow remains negative, reflecting high capital expenditures relative to operating cash flow. The free cash flow to net income ratio is negative, posing potential liquidity challenges.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	21.34B	20.80B	18.31B	16.56B	14.83B	7.07B
Gross Profit	6.23B	6.47B	5.26B	2.80B	2.29B	2.29B
EBITDA	2.70B	2.65B	2.57B	2.12B	1.94B	1.31B
Net Income	1.35B	1.36B	1.31B	1.07B	976.74M	802.20M
Balance Sheet
Total Assets	0.00	18.96B	15.72B	13.68B	12.57B	5.61B
Cash, Cash Equivalents and Short-Term Investments	1.17B	1.14B	667.85M	1.52B	644.26M	883.57M
Total Debt	0.00	2.18B	1.19B	739.28M	84.27M	0.00
Total Liabilities	-11.85B	7.11B	5.24B	4.52B	4.52B	1.53B
Stockholders Equity	11.85B	11.85B	10.48B	9.15B	8.05B	4.09B
Cash Flow
Free Cash Flow	0.00	-210.69M	-880.28M	1.20B	-88.67M	-103.17M
Operating Cash Flow	0.00	1.37B	432.55M	1.52B	293.58M	477.67M
Investing Cash Flow	0.00	-1.84B	-1.03B	-1.81B	-2.99B	-371.79M
Financing Cash Flow	0.00	649.01M	161.85M	608.55M	2.92B	-245.92M

Rossari Biotech Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 579.65
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ROSSARI, the sentiment is Negative. The current price of 579.65 is below the 20-day moving average (MA) of 588.47, below the 50-day MA of 619.98, and below the 200-day MA of 651.49, indicating a bearish trend. The MACD of -13.27 indicates Positive momentum. The RSI at 37.34 is Neutral, neither overbought nor oversold. The STOCH value of 29.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ROSSARI.

Rossari Biotech Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FCL	75 Outperform	₹27.50B	28.04	―	0.67%	-10.12%	-22.38%
ROSSARI	70 Outperform	₹31.54B	23.08	―	0.09%	15.47%	-1.72%
BHARATRAS	65 Neutral	₹38.21B	28.69	―	0.02%	6.39%	-15.53%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
KIRIINDUS	60 Neutral	₹34.16B	26.36	―	―	-22.04%	-58.81%
ORISSAMINE	45 Neutral	₹27.85B	―	―	―	-27.80%	-365.69%

Rossari Biotech Ltd Corporate Events

Rossari Biotech’s Credit Rating Reaffirmed by ICRA

Rossari Biotech Ltd has announced that ICRA Limited has reaffirmed its credit ratings, maintaining a positive outlook for its long-term and short-term financial instruments. This reaffirmation of credit ratings reflects the company’s strong financial position and operational stability, which is likely to enhance its credibility and attractiveness to investors and stakeholders.

Rossari Biotech Subsidiary Secures Leasehold Land in Gujarat

Rossari Biotech Ltd announced that its subsidiary, Unitop Chemicals Private Limited, has received approval from the Gujarat Industrial Development Corporation (GIDC) to acquire rights in a leasehold land in Dahej, Gujarat. This acquisition, covering approximately 12,608 square meters, is expected to enhance Unitop’s operational capabilities and strengthen Rossari’s position in the specialty chemicals market, potentially benefiting stakeholders through increased production capacity and market reach.

Rossari Biotech Affirms Regulatory Compliance for Q3 2025

Rossari Biotech Ltd has released a compliance certificate under Regulation 74(5) of SEBI for the quarter ended September 30, 2025. The certificate confirms that all securities received for dematerialisation were processed appropriately, with shares being mutilated and cancelled after verification. This announcement underscores the company’s commitment to regulatory compliance and transparency in its operations, which is crucial for maintaining stakeholder trust and ensuring smooth market operations.

Rossari Biotech Announces Trading Window Closure Ahead of Financial Results

Rossari Biotech Ltd has announced the closure of its trading window in compliance with SEBI’s insider trading regulations, effective from October 1, 2025, until 48 hours after the announcement of its unaudited financial results for the quarter and half-year ending September 30, 2025. This move is part of the company’s adherence to its Code of Conduct for Prevention of Insider Trading, ensuring transparency and regulatory compliance, which is crucial for maintaining stakeholder trust and market integrity.

Rossari Biotech to Engage with Investors and Analysts in Upcoming Meeting

Rossari Biotech Ltd has announced its participation in an upcoming investor and analyst meeting organized by Haitong Securities Group on September 19, 2025. The meeting will cover financial and other publicly available information, ensuring no unpublished price-sensitive information is disclosed. This engagement underscores Rossari’s commitment to transparency and maintaining strong relationships with investors and analysts.